GlucoTrack, Inc. reported a net loss of approximately $19.4 million for the fiscal year ending December 31, 2025, a decrease from a net loss of $22.6 million in the previous year. The company’s accumulated deficit now stands at about $151.8 million. Total revenue remains negligible as the company has not yet commercialized its primary product, the Glucotrack Continuous Blood Glucose Monitor (CBGM), which is still under development. Research and development expenses increased slightly to $9.8 million from $9.5 million, reflecting ongoing efforts in product design and clinical trials. General and administrative expenses also rose to $6.3 million, up from $5.0 million, primarily due to higher professional fees and personnel costs.
In 2023, GlucoTrack made a strategic decision to withdraw its CE Mark for its first-generation product and focus on the development of the Glucotrack CBGM, which aims to provide continuous glucose monitoring for individuals with Type 1 and Type 2 diabetes. The company acquired relevant intellectual property from its CEO, Paul V. Goode, to enhance its product development efforts. The Glucotrack CBGM is designed to offer improved accuracy and convenience compared to existing glucose monitoring solutions, with a projected implant longevity of up to three years.
Operationally, GlucoTrack has made significant progress in its clinical studies. The company completed a first-in-human study in 2025, which demonstrated the safety and functionality of the device. Additionally, a multicenter feasibility study in Australia provided valuable insights, although the company decided to close this study due to complexities in patient eligibility and product updates. GlucoTrack is currently preparing for a U.S. clinical trial program, with plans to submit an Investigational Device Exemption (IDE) to the FDA in the second quarter of 2026.
As of December 31, 2025, GlucoTrack had $7.4 million in cash and cash equivalents, an increase from $5.6 million the previous year. However, the company expressed substantial doubt about its ability to continue as a going concern without additional capital, as its current cash reserves may not be sufficient to fund operations for the next twelve months. The company is actively seeking to raise funds through various means, including equity and debt financing, but there are no guarantees that it will secure the necessary capital on favorable terms.
Looking ahead, GlucoTrack aims to advance its clinical trial activities and continue developing the Glucotrack CBGM. The company is also focused on addressing its internal control weaknesses, which were identified in its financial reporting processes. Management has initiated corrective actions, including hiring additional accounting personnel and implementing an enterprise resource planning system to enhance operational efficiency and compliance. The success of these initiatives, along with the approval and market acceptance of the Glucotrack CBGM, will be critical for the company's future growth and financial stability.
About GlucoTrack, Inc.
Glucotrack, Inc. develops innovative medical devices focused on non-invasive and implantable continuous blood glucose monitoring systems for people with Type 1 and insulin-dependent Type 2 diabetes. Its core product, the Glucotrack CBGM, aims to provide long-term, accurate, and convenient glucose measurement without fingersticks. The company targets the growing diabetes market, leveraging advanced sensor technology, regulatory expertise, and strategic manufacturing partnerships to improve patient outcomes and address unmet needs in glucose management.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.